Survival was substantially greater with hemodialysis versus no hemodialysis in patients with peak salicylate levels >50 mg/dL.
For patients with salicylate poisoning, hemodialysis is the definitive treatment. To assess how hemodialysis affects survival in such patients, investigators reviewed data on 56 intubated salicylate-poisoned cases reported to the Illinois Poison Center from 2003 through 2014.
Among patients with a serum salicylate level greater than 50 mg/dL, 73% survived. Among those who did not receive hemodialysis, survival was 56% for peak salicylate levels >50 mg/dL, and 0% when the level was >80 mg/dL. Among those who received hemodialysis, 84% of those with a peak salicylate level >50 mg/dL survived, and 83% survived when the level was >80 mg/dL.
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals